Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Industry, Sector and Symbol
Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
Phone314-996-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$100.06 billion
Profitability
Miscellaneous
Employees26,600
OptionableOptionable
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How will Express Scripts' stock buyback program work?
Express Scripts declared that its Board of Directors has initiated a stock repurchase program on Wednesday, December 20th 2017, which permits the company to repurchase 45,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its shares are undervalued.
How were Express Scripts' earnings last quarter?
Express Scripts Holding Co (NASDAQ:ESRX) issued its quarterly earnings results on Wednesday, October, 31st. The company reported $2.43 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.42 by $0.01. The firm had revenue of $25.56 billion for the quarter, compared to the consensus estimate of $25.11 billion. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. Express Scripts's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.51 EPS. View Express Scripts' Earnings History.
When is Express Scripts' next earnings date?
What price target have analysts set for ESRX?
14 Wall Street analysts have issued 1-year price objectives for Express Scripts' shares. Their forecasts range from $77.00 to $101.00. On average, they anticipate Express Scripts' stock price to reach $92.65 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Express Scripts.
What is the consensus analysts' recommendation for Express Scripts?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Express Scripts in the last year. There are currently 1 sell rating, 11 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Express Scripts.
Has Express Scripts been receiving favorable news coverage?
News stories about ESRX stock have trended neutral recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Express Scripts earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Express Scripts' key competitors?
Who are Express Scripts' key executives?
Express Scripts' management team includes the folowing people:
- Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
- Mr. James M. Havel, Exec. VP & CFO (Age 63)
- Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
- Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
- Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)
Who are Express Scripts' major shareholders?
Express Scripts' stock is owned by many different of institutional and retail investors. Top institutional investors include Meiji Yasuda Asset Management Co Ltd. (0.00%) and Wealthquest Corp (0.00%). Company insiders that own Express Scripts stock include Christine Houston, Everett Neville, Glen D Stettin, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Which major investors are selling Express Scripts stock?
ESRX stock was sold by a variety of institutional investors in the last quarter, including Meiji Yasuda Asset Management Co Ltd.. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville and Mahon Thomas P Mac. View Insider Buying and Selling for Express Scripts.
Which major investors are buying Express Scripts stock?
How do I buy shares of Express Scripts?
Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of ESRX stock can currently be purchased for approximately $92.33.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $52.06 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.
What is Express Scripts' official website?
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (NASDAQ ESRX)
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
